US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

42.61

+0.93212.24%

Post-market: 42.680.0729+0.17%16:10 EDT

Volume:561

Turnover:23.88K

Market Cap:118.32M

PE:- -

High:42.68

Open:42.52

Low:42.52

Close:41.68

52wk High:48.78

52wk Low:29.44

Shares:2.78M

Float Shares:2.78M

Volume Ratio:0.36

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

LivaNova Director Brooke Story Sells 2,300 Shares for $187,270.14

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)

Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis

MT Newswires Live

Video: Novartis slides after second recent drug development setback

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co

Spyre Therapeutics announces 12-week induction data from Part A of SKYLINE trial

Spyre Reports Positive Phase 2 Skyline Part a Induction Data for UC Drug Spy003, Hits Primary Endpoint

Spyre Therapeutics - Spy003 Meets Primary Endpoint with 10.0-Point Rhi Reduction at Week 12

THOMSON REUTERS

Spyre Therapeutics - Spy003 Well Tolerated with Safety Profile Consistent with Il-23 Class

THOMSON REUTERS

Spyre Therapeutics - Spy003 Achieves 20% Clinical Remission and 30% Endoscopic Improvement at Week 12

THOMSON REUTERS

Spyre Therapeutics - Skyline Part B Enrolling; Topline Induction Data Expected in 2027

THOMSON REUTERS

Guardant Health's Breast Cancer Diagnostic Approved by US FDA

MT Newswires Live

Rothschild & Co Redburn Initiates Guardant Health at Buy

MT Newswires Live

Guardant Health initiated with a Buy at Rothschild & Co Redburn

Milton Essex boosts Sanford Biotech capital to drive advanced mastitis cell therapy

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LFSC/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":42.6071,"timestamp":1791576000000,"preClose":41.675,"halted":0,"volume":561,"hourTrading":{"tag":"盘后","latestPrice":42.68,"preClose":42.6071,"latestTime":"16:10 EDT","volume":1,"amount":42.6071,"timestamp":1791576604081,"change":0.0729,"changeRate":0.001711,"amplitude":0},"delay":0,"changeRate":0.022365926814637206,"floatShares":2777035,"shares":2777035,"eps":0,"marketStatus":"Market Closed","change":0.9321,"latestTime":"10-09 16:00:00 EDT","open":42.515,"high":42.68,"low":42.515,"amount":23883,"amplitude":0.003959,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":41.675,"sharesOutstanding":2657035,"nav":41.68,"aum":115746818.8,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.68,"preClose":42.6071,"latestTime":"16:10 EDT","volume":1,"amount":42.6071,"timestamp":1791576604081,"change":0.0729,"changeRate":0.001711,"amplitude":0},"volumeRatio":0.35855808645794174},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2777035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.35855808645794174,"shares":2777035,"dividePrice":0,"high":42.68,"amplitude":0.003959,"preClose":41.675,"low":42.515,"week52Low":29.4441,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":42.6071,"eps":0,"divideRate":0,"volume":561,"delay":0,"ttmEps":0,"open":42.515,"prevYearClose":36.6147,"prevWeekClose":43.401,"prevMonthClose":44.5697,"prevQuarterClose":44.5697,"fiveDayClose":43.401,"twentyDayClose":45.3275,"sixtyDayClose":44.9054},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666370307","title":"LivaNova Director Brooke Story Sells 2,300 Shares for $187,270.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370307","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370307?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:02","pubTimestamp":1788901342,"startTime":"0","endTime":"0","summary":"LivaNova director Brooke Story sells 2,300 shares for $187,270.14LivaNova director Brooke Story sold 2,300 ordinary shares on Sep. 4, 2026 at USD 81.42 each.Direct holdings fell to 7,488 ordinary shar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL1gkKlF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"LivaNova Director Brooke Story Sells 2,300 Shares for $187,270.14","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","LU2065170008.USD","LU2065171311.SGD","LIVN","BK4082","LU2065171402.SGD","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FXH","MDTX","MNTL","FHLC","BBH","HYLG","BBP","CURE","CNCR","SURI","SYNB","IBBJ","XPH","FBT","JDOC","NVIB","GNOM","MEDX","SBIO","PSCH","APXH","PJP","AZNH","PBE","PTH","IBB","BME","TBXU","GDOC","IBBQ","PSIL","IDNA","IBRN","RSPH","MEDI","IEIH","MRNY","CANC","JHMH","LFSC","PINK","HRTS","LLYX","GNMX","PBPH","GPCR","BIB","FTXH","WDNA","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374637","title":"Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374637?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:20","pubTimestamp":1788888012,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and BioCryst (BCRX) with b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-biocryst-bcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-biocryst-bcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","LU0128526141.USD","BK4581","BCRX","LFSC","BK4137","LABU","BK4585","XBI","XLV","BK4547","BK4139","LU0029874061.USD","SYRE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375642","title":"Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375642","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375642?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:35","pubTimestamp":1788874514,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics'  SPY003 met the primary endpoint in the phase 2 Skyline trial, reducing the Robarts Histopathology Index score by 10 points at week 12 in patients with moderately to severely active ulcerative colitis, the company said Tuesday.The anti-IL-23 therapy achieved a 20% clinical-remission rate, measured by modified Mayo Score, and a 30% endoscopic-improvement rate, while remaining well tolerated with a safety profile consistent with the IL-23 class, the company said.The results complete clinical proof-of-concept for all three components of Spyre's IBD strategy, with part B of the SKYLINE trial evaluating pairwise combinations now enrolling.Spyre expects topline SKYLINE part B induction data in 2027, with phase 2 SKYWAY results for SPY072 in psoriatic arthritis and axial spondyloarthritis expected in the fourth quarter of 2026, it added.Spyre Therapeutics shares were down 1.1% in premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SYRE","LFSC","BK4539","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665858375","title":"Video: Novartis slides after second recent drug development setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2665858375","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665858375?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:05","pubTimestamp":1788872716,"startTime":"0","endTime":"0","summary":"The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will open, which stocks will...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/video-novartis-slides-after-second-recent-drug-development-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/video-novartis-slides-after-second-recent-drug-development-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","BMED","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665373511","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665373511?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:51","pubTimestamp":1788871865,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN), Guardant Health (GH) and Neurocrine (N...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","BK4535","LU0823416689.USD","IBB","LU0029874061.USD","LU1061106388.HKD","LU0109394709.USD","LU1571399168.USD","EKG","BK4599","TBXU","LU0889565916.HKD","LU0154245756.USD","BK4137","IE0002141913.USD","PBE","BK4534","IE00BJT1NW94.SGD","LU2468319806.SGD","BK4585","IE0009355771.USD","BK4139","LU1057294990.SGD","AMGN","PTH","PJP","HCSG","BIB","GH","LFSC","XLV","IE00BFTCPJ56.SGD","LU0154245673.USD","LU0058720904.USD","NBIX","GNOM","BBH","BK4588","XBI","GNMX","IE00B2B36J28.USD","LU2065170008.USD","LU2242646821.SGD","FFOX","LU0289739699.SGD","GDOC","IBBQ","LABU","LU2242652126.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZNH","PBE","FHLC","SURI","PINK","RSPH","PBPH","APXH","IDNA","BIB","HRTS","GNMX","IBBJ","IBRN","NVIB","HYLG","GSKH","GPCR","BBH","PSIL","XPH","PJP","MDTX","MEDI","JDOC","CNCR","FBT","LLYX","FXH","JHMH","WDNA","SYNB","FTXH","MNTL","MEDX","PSCH","LENZ","CURE","GDOC","IBB","MRNY","BBP","GNOM","LFSC","TBXU","PTH","SBIO","IBBQ","CANC","BME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378332","title":"Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378332?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:26","pubTimestamp":1788870360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4585","BK4551","BK4196","LU0889565916.HKD","BK4588","GH","LU0320765992.SGD","GNOM","BK4535","EKG","FFOX","HELX","PTH","LFSC","GDOC","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320733","title":"Spyre Therapeutics announces 12-week induction data from Part A of SKYLINE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320733?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:15","pubTimestamp":1788869740,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) announced positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 being investi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-12-week-induction-data-from-part-a-of-skyline-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-12-week-induction-data-from-part-a-of-skyline-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4539","LFSC","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320564","title":"Spyre Reports Positive Phase 2 Skyline Part a Induction Data for UC Drug Spy003, Hits Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320564","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320564?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868896,"startTime":"0","endTime":"0","summary":"Spyre reports positive Phase 2 SKYLINE Part A induction data for UC drug SPY003, hits primary endpointSpyre Therapeutics reported positive 12-week induction results from Part A of its Phase 2 SKYLINE ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL1KRyb1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4139","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","NDAQ","LFSC","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BCDF","SYRE","IE00BQXX3C00.GBP","LU2210150020.SGD","BK4588","LU2210149790.SGD","LU0314104364.USD","BK4112","IE00B64PRP62.GBP","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4585","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665544320","title":"Spyre Therapeutics - Spy003 Meets Primary Endpoint with 10.0-Point Rhi Reduction at Week 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2665544320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665544320?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868808,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA7PFYB1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320546","title":"Spyre Therapeutics - Spy003 Well Tolerated with Safety Profile Consistent with Il-23 Class","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320546?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868808,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA7PFYB1:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320514","title":"Spyre Therapeutics - Spy003 Achieves 20% Clinical Remission and 30% Endoscopic Improvement at Week 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320514?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868808,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA7PFYB1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665205113","title":"Spyre Therapeutics - Skyline Part B Enrolling; Topline Induction Data Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2665205113","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665205113?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA7PFYB1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321994","title":"Guardant Health's Breast Cancer Diagnostic Approved by US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321994","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321994?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:08","pubTimestamp":1788862114,"startTime":"0","endTime":"0","summary":"Guardant Health's  Guardant360 CDx has been approved by the US Food and Drug Administration as a companion diagnostic for advanced metastatic breast cancer, the company said Friday.The specific indication for the diagnostic combination is to identify patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with specific mutations before radiographic progression who may benefit from treatment with AstraZeneca's  Etcamah, the company said.The approval is based on data from a clinical trial showing a 56% reduction in the risk of progression or death, the company said.Shares of the company were up 1% in recent premarket trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0029864427.USD","AZN","BK4588","AZNH","GNOM","LFSC","LABU","BK4535","LU2237443622.USD","GDOC","EKG","LU0109394709.USD","LU0128525929.USD","GH","HELX","GNMX","BK4196","BK4585","LU2089984988.USD","LU0708994859.HKD","LU1267930573.SGD","FFOX","LU1829250122.USD","LU2417539215.USD","LU2237443978.SGD","LU0320765992.SGD","LU2237443895.HKD","BK4568","LU2237443465.HKD","BK4551","LU0432979614.USD","LU0889565916.HKD","LU0310800379.SGD","LU2456880835.USD","LU2468319806.SGD","PTH","BK4007","LU2237443382.USD","LU0289739699.SGD","LU2462157665.USD","IE00B3T34201.USD","LU0058720904.USD","LU2236285917.USD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665213403","title":"Rothschild & Co Redburn Initiates Guardant Health at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665213403","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665213403?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:01","pubTimestamp":1788861705,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","EKG","HELX","GNMX","BK4585","FFOX","BK4588","LU0320765992.SGD","LU0889565916.HKD","BK4196","GNOM","PTH","LFSC","BK4551","BK4535","GDOC","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532615","title":"Guardant Health initiated with a Buy at Rothschild & Co Redburn","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532615?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:16","pubTimestamp":1788858969,"startTime":"0","endTime":"0","summary":"Rothschild & Co Redburn initiated coverage of Guardant Health (GH) with a Buy rating and $203 price target The firm says Guardant is the leader in ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","BK4588","LFSC","GNMX","BK4551","LU0320765992.SGD","PTH","BK4535","HELX","BK4585","EKG","GH","FFOX","GNOM","GDOC","LU0889565916.HKD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665101723","title":"Milton Essex boosts Sanford Biotech capital to drive advanced mastitis cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665101723","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665101723?lang=en_us&edition=fundamental","pubTime":"2026-09-08 02:47","pubTimestamp":1788806848,"startTime":"0","endTime":"0","summary":"MILTON ESSEX S.A. ( ($PL:MTN) ) just unveiled an announcement. Milton Essex S.A., acting as sole shareholder of Sanford Biotech, has approved a PLN...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/milton-essex-boosts-sanford-biotech-capital-to-drive-advanced-mastitis-cell-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/milton-essex-boosts-sanford-biotech-capital-to-drive-advanced-mastitis-cell-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","FBT","GNOM","TBXU","SYNB","BK4588","BK4585","BK4581","IBB","XBI","IBBQ","CNCR","MTNmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354019","title":"Guardant announces FDA approval of Guardant360 CDx as companion diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354019","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354019?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:15","pubTimestamp":1788560112,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that the U.S. Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic to identify patien...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","HELX","GDOC","LU0889565916.HKD","PSCH","SYNB","LU0320765992.SGD","PTH","FFOX","PINK","GNOM","EKG","BK4535","MRNY","NVIB","BMED","LABU","LFSC","IEIH","TBXU","IBB","GH","IYH","BK4196","IDNA","BK4588","GNMX","MRNX","BK4585","RSPH","FRTY","MEDI","LU0109394709.USD","TECB","BK4551","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354794","title":"Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354794?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:10","pubTimestamp":1788559800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA7GZLSJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4551","BK4196","GDOC","HELX","BK4588","GNMX","LU0109394709.USD","FFOX","LFSC","PTH","GH","BK4585","LU0889565916.HKD","LU0320765992.SGD","GNOM","EKG","BK4535"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}